#fda - CRISPR Therapeutics (CRSP): ARK's Stock Stories: ARK Invest

25 August 2026

For 30 years, the standard of care for sickle cell disease was a drug that managed symptoms without touching the underlying genetic defect. In December 2023, the Food And Drug Administration (FDA) approved a functional cure.

CASGEVY, built by CRISPR Therapeutics and commercialized with Vertex Pharmaceuticals, has treated less than 0.1% of its 60,000 eligible patients.

ARK's bottoms-up model sees roughly $5 billion in cumulative revenue through 2029, versus Wall Street consensus of $1 to 2 billion.

CRISPR Therapeutics AG: Crispr Earnings: Casgevy Gains Traction as Commercial Hurdles Begin to Ease